HARBIN, China, Oct. 25, 2011 /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, today announced that the Company has recently hosted a technical exchange between 13 senior research specialists in the field of Traditional Chinese Medicine (TCM) and herbal medicine.
China Botanic participated in the technical exchange with leading research specialists of the TCM industry at the Company's headquarters to review the Company's scientific endeavors. The technical exchange gathering included Mr. Jisheng Chen, a noted medical scholar from the China Academy of Engineering, Mr. Zhengwu Qi, an acclaimed researcher from the China Academy of Sciences, and other well-known scientists and professors specializing in bio-pharmaceutical biological research from China's leading universities and research institutes. Mr. Chen is a pharmaceutical chemist and is renowned for his knowledge of natural medicine chemistry and drug design. Mr. Qi is also a well-known biochemist and a leader in protein and peptide research.
The leading research specialists recognized the Company's noteworthy achievements in creating effective, plant-based medicines and offered recommendations for further advances. The Company also received suggestions on institutes which may potentially collaborate with China Botanic in researching all-natural plant-based remedies.
"We thank all our distinguished guests for their positive feedback and appreciation of our Siberian Ginseng series and other products," commented Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic. "We believe the technical exchange was a great success and China Botanic's research team benefited from the opportunity to discuss ideas with industry leading experts. The positive review of our products further strengthens our commitment towards becoming a leading global provider of all-natural and plant-based medicines."
ABOUT CHINA BOTANIC PHARMACEUTICAL INC.China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, please visit www.renhuang.com.
Safe Harbor StatementThis press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and financial performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.Company Contact:
CCG Investor Relations:China Botanic Pharmaceutical Inc
Mr. Mark Collinson, PartnerMs. Portia Tan, IR Contact
Phone: +1-310-954-1343 (Los Angeles)Tel: 86-451-8260-2162
Email: email@example.comEmail: firstname.lastname@example.org
|SOURCE China Botanic Pharmaceutical Inc.|
Copyright©2010 PR Newswire.
All rights reserved